Cholera Vaccines Market Size, Share, Trends, Growth Outlook

Cholera Vaccines Market is estimated to increase at a growth rate of 9.2% CAGR over the forecast period from 2024 to 2030.

The Cholera Vaccines Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Vaccine (Whole cell V. cholerae O1 with Recombinant B-subunit, Killed Oral O1 and O139), By Product (Vaxchora, Dukoral, Shanchol, Others).

An Introduction to Cholera Vaccines Market in 2024

The Cholera Vaccines market in 2024 addresses the global demand for vaccines targeting Vibrio cholerae infections, a significant cause of diarrheal disease and outbreaks in resource-limited settings. Cholera vaccines include oral and injectable formulations based on inactivated whole-cell or live-attenuated strains of V. cholerae, offering options for both prevention and outbreak control. Market dynamics are driven by factors such as the endemicity of cholera in regions with poor sanitation and water quality, advancements in vaccine development and delivery strategies, and the demand for pre-travel and humanitarian vaccination campaigns. Collaboration between vaccine manufacturers, public health organizations, non-governmental organizations (NGOs), and regulatory agencies drives innovation and accessibility in cholera vaccines, contributing to the global efforts to eliminate cholera as a public health threat.

Cholera Vaccines Market Trend: Increased Focus on Preventive Healthcare

A prominent trend in the Cholera vaccine market is the growing emphasis on preventive healthcare measures, including vaccination programs, to mitigate the risk of cholera outbreaks. Governments, international health organizations, and non-governmental organizations are increasingly recognizing the importance of vaccination as a cost-effective strategy for controlling cholera transmission, particularly in regions prone to epidemics. This trend is driving the demand for cholera vaccines globally, leading to expanded immunization campaigns and initiatives aimed at achieving broader vaccine coverage among at-risk populations.

Cholera Vaccines Market Driver: Rising Incidence of Cholera Outbreaks

The primary driver for the Cholera vaccine market is the escalating incidence of cholera outbreaks worldwide, fueled by factors such as inadequate access to clean water and sanitation facilities, population displacement due to conflicts or natural disasters, and environmental changes. Cholera remains a significant public health concern, particularly in low- and middle-income countries where infrastructure deficiencies contribute to the spread of the disease. In response to the persistent threat of cholera epidemics, governments, and health authorities are intensifying efforts to strengthen vaccination programs and improve access to cholera vaccines, driving market growth.

Cholera Vaccines Market Opportunity: Expansion of Market Access and Distribution Channels

An opportunity in the Cholera vaccine market lies in the expansion of market access and distribution channels to reach underserved populations in high-risk areas. Despite the availability of cholera vaccines, challenges such as logistical barriers, vaccine affordability, and vaccine hesitancy hinder the equitable distribution and uptake of vaccines in some regions. By investing in innovative distribution strategies, such as mobile vaccination clinics, community outreach programs, and public-private partnerships, vaccine manufacturers and stakeholders can improve vaccine accessibility and coverage in remote or marginalized communities. Additionally, addressing socioeconomic factors that contribute to vaccine hesitancy and collaborating with local health authorities to build trust and raise awareness about the importance of vaccination can further enhance market penetration and contribute to cholera prevention efforts.

Cholera Vaccines Market Segmentation

By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Cholera Vaccines Market Companies

Astellas Pharma Inc
Emergent BioSolutions Inc
GlaxoSmithKline plc (GSK)
Merck & Co. Inc
Mitsubishi Tanabe Pharma Corp
PaxVax Inc
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co. Ltd
Valneva SE

 

 

Reasons to Buy the Cholera Vaccines Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cholera Vaccines Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cholera Vaccines Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Cholera Vaccines Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cholera Vaccines Market Size Outlook, $ Million, 2021 to 2030
3.2 Cholera Vaccines Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cholera Vaccines Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cholera Vaccines Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cholera Vaccines Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cholera Vaccines Market Industry
4.2 Key Market Trends in Cholera Vaccines Market Industry
4.3 Potential Opportunities in Cholera Vaccines Market Industry
4.4 Key Challenges in Cholera Vaccines Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Cholera Vaccines Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cholera Vaccines Market Outlook By Segments
7.1 Cholera Vaccines Market Outlook by Segments
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

8 North America Cholera Vaccines Market Analysis And Outlook To 2030
8.1 Introduction to North America Cholera Vaccines Markets in 2024
8.2 North America Cholera Vaccines Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cholera Vaccines Market size Outlook by Segments, 2021-2030
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

9 Europe Cholera Vaccines Market Analysis And Outlook To 2030
9.1 Introduction to Europe Cholera Vaccines Markets in 2024
9.2 Europe Cholera Vaccines Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cholera Vaccines Market Size Outlook By Segments, 2021-2030
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

10 Asia Pacific Cholera Vaccines Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Cholera Vaccines Markets in 2024
10.2 Asia Pacific Cholera Vaccines Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cholera Vaccines Market size Outlook by Segments, 2021-2030
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

11 South America Cholera Vaccines Market Analysis And Outlook To 2030
11.1 Introduction to South America Cholera Vaccines Markets in 2024
11.2 South America Cholera Vaccines Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cholera Vaccines Market size Outlook by Segments, 2021-2030
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

12 Middle East And Africa Cholera Vaccines Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Cholera Vaccines Markets in 2024
12.2 Middle East and Africa Cholera Vaccines Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cholera Vaccines Market size Outlook by Segments, 2021-2030
By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Astellas Pharma Inc
Emergent BioSolutions Inc
GlaxoSmithKline plc (GSK)
Merck & Co. Inc
Mitsubishi Tanabe Pharma Corp
PaxVax Inc
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co. Ltd
Valneva SE

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Vaccine Type
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Product
Vaxchora
Dukoral
Shanchol
Others